Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
Question
Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
Direct answer
A 42% objective response rate and 16.0-month median overall survival in RAS-mutant NSCLC enhances pipeline commercial net present value for RVMD. — bullish pressure on RVMD via clinical pipeline validation and increased regulatory approval probability.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-03
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM”, revision 1, evidence through 2026-09-03. https://marketontology.com/catalysts/2026-09-03/revolution-medicines-publishes-phase-1-2-data-for-daraxonrasib-in-nejm-e9900f
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| RVMD | ▲Bull | 1–4 weeks | clinical pipeline validation and increased regulatory approval probability | 68 |
Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
A 42% objective response rate and 16.0-month median overall survival in RAS-mutant NSCLC enhances pipeline commercial net present value for RVMD. — bullish pressure on RVMD via clinical pipeline validation and increased regulatory approval probability.
NEJM publication showed 42% ORR and 16.0 months median OS for daraxonrasib in RAS mutant NSCLC.
- SourceNEJM publication showed 42% ORR and 16.0 months median OS for daraxonrasib in RAS mutant NSCLC.
- TransmissionA 42% objective response rate and 16.0-month median overall survival in RAS-mutant NSCLC enhances pipeline commercial net present value for RVMD.
- SummaryNEJM published Phase 1/2 clinical results for daraxonrasib in RAS-mutant NSCLC. The trial demonstrated a 42% objective response rate and 16.0 months median overall survival. The validation strengthens Revolution Medicines' clinical positioning in targeted oncology.
- RVMDDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- RVMD closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- RVMD price vs. pre-event level
- RVMD volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer · news_wire · 2026-09-02
Related catalysts
- 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer DataRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung CancerRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo SurvivalRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORRRVMD
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE as First Broad RAS InhibitorIMRX RVMD
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.